Metabolic disease companies develop therapies, diagnostics and research technologies for disorders affecting how the body processes and stores energy. Their work spans diabetes, obesity, fatty liver disease and inherited metabolic conditions.
This category includes companies working on:
Browse 53 UK metabolic disease companies below.
Structure-guided small-molecule therapeutics for antiviral and metabolic diseases
Halo Therapeutics is a University of Bristol spinout developing structure-guided small-molecule medicines for infectious and metabolic diseases. Its research combines cryo-electron microscopy, protein biophysics and computational chemistry to identify drug-binding pockets and design selective compounds. Its antiviral…
Global IVD company specialising in point-of-care diagnostics and life sciences
EKF Diagnostics is an AIM-listed global in vitro diagnostics company headquartered in Penarth, near Cardiff. The group develops and manufactures point-of-care analysers for haemoglobin, HbA1c, glucose, lactate, and ketone measurement, alongside a central laboratory reagent and rapid test portfolio distributed to over…
Small molecule therapeutics targeting lipid-signalling pathways
Artelo Biosciences is a clinical-stage biopharmaceutical company developing small molecule therapeutics that modulate lipid-signalling pathways, including the endocannabinoid system. Its pipeline includes ART27.13, a peripherally selective cannabinoid receptor agonist in Phase 2 for cancer-associated anorexia and…
Cambridge R&D hub for GPCR-based drug discovery
Nxera Pharma UK is the Cambridge-based drug discovery arm of Tokyo-listed Nxera Pharma, formerly Sosei Heptares, operating from Granta Park with approximately 170 scientists. Its structure-based drug discovery capabilities have produced over 50 resolved GPCR structures. Following a restructuring in November 2025, the…
Engineered probiotic bacteria producing peptide therapeutics inside the body
Hijack Bio develops engineered probiotic bacteria designed to produce and release peptide therapeutics inside the body. The synthetic biology approach aims to reduce reliance on conventional external manufacturing and cold-chain distribution while enabling oral delivery of peptide drugs. Potential applications include…
AI-guided RNA therapies for chronic metabolic diseases
Elarna Bio is a biotechnology company developing long-acting RNA therapeutics for chronic metabolic diseases. It combines AI-driven discovery with RNA engineering to improve the duration of therapeutic activity. The platform focuses on challenges associated with liver-targeted RNA treatments and is intended for…
Experimental diabetes research into insulin and metabolic therapies
Centre for Diabetes is an Ulster University research centre in Coleraine investigating the molecular mechanisms of diabetes and emerging treatment approaches. Its research includes pancreatic beta-cell dysfunction, insulin secretion, glycation, glucose-regulating peptides and experimental antidiabetic compounds. The…
European commercialisation partner for specialty and rare disease medicines
Abacus Medicine Pharmaceuticals is a commercial-stage pharmaceutical company that partners with pharmaceutical and biotechnology developers to launch and commercialise specialty medicines across Europe. It can act as a regional affiliate in selected markets or manage wider European rollouts, covering regulatory,…
Cell therapy for vascular regeneration in ischaemic and wound healing conditions
VascVersa is a Belfast-based regenerative medicine company developing cell therapies for vascular regeneration and repair. The company's technology uses vasoreparative cells to stimulate new blood vessel formation and restore blood supply in conditions characterised by impaired circulation. The lead programme targets…
Proprietary formulation platform enhancing diabetes and cardiometabolic therapies
Arecor Therapeutics is a biopharmaceutical company developing enhanced formulations of existing therapeutic products for diabetes and cardiometabolic diseases. Its proprietary formulation technology improves stability, concentration and delivery profiles for biologics and peptides, supporting both in-house programmes…
Mitochondrial transplantation platform to restore cellular energy and regeneration
Recondria Therapeutics is a developer of a mitochondrial transplantation platform designed to restore cellular energy, accelerate tissue recovery and support regenerative medicine. The company's approach involves isolating healthy mitochondria and delivering them to damaged cells to restore ATP production and cellular…
Pharmaceutical company in cardiometabolic, oncology, and immunology
Eli Lilly and Company is a multinational pharmaceutical company with UK operations headquartered in Basingstoke and an R&D site in Bracknell. Founded in 1876, Lilly's UK affiliate has operated since 1934 and employs approximately 700 people across regulatory, medical affairs, and research functions. The company…
Independent global health research institute focused on chronic diseases
The George Institute for Global Health (UK) is an independent medical research institute conducting large-scale clinical trials, population studies, and health policy research on non-communicable diseases. Based at Imperial College London's White City Campus and affiliated with Imperial as a strategic partner, the UK…